CL2007003583A1 - Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. - Google Patents

Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.

Info

Publication number: CL2007003583A1
Authority: CL; Chile
Prior art keywords: formulation; abeta; alzheimer; disease; stable
Prior art date: 2006-12-11

Application number

CL200703583A

Other languages

English (en)

Inventor

Goldbach Hanns-Christia Pierre

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-11

Filing date

2007-12-11

Publication date

2008-07-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39190366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003583(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-11 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-07-18 Publication of CL2007003583A1 publication Critical patent/CL2007003583A1/es

Links

DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 2
208000024827 Alzheimer disease Diseases 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Neurology (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL200703583A 2006-12-11 2007-12-11 Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. CL2007003583A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06025590		2006-12-11

Publications (1)

Publication Number	Publication Date
CL2007003583A1 true CL2007003583A1 (es)	2008-07-18

Family

ID=39190366

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200703583A CL2007003583A1 (es)	2006-12-11	2007-12-11	Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.

Country Status (21)

Country	Link
US (1)	US20110070225A1 (es)
EP (1)	EP2094729A1 (es)
JP (1)	JP2010512356A (es)
KR (1)	KR20090104017A (es)
CN (1)	CN101553504A (es)
AR (1)	AR064220A1 (es)
AU (1)	AU2007331712A1 (es)
BR (1)	BRPI0721097A2 (es)
CA (1)	CA2671968A1 (es)
CL (1)	CL2007003583A1 (es)
CR (1)	CR10823A (es)
EC (1)	ECSP099403A (es)
IL (1)	IL198963A0 (es)
MA (1)	MA30975B1 (es)
MX (1)	MX2009006199A (es)
NO (1)	NO20092586L (es)
PE (1)	PE20081477A1 (es)
RU (1)	RU2009126420A (es)
TW (1)	TW200831133A (es)
WO (1)	WO2008071394A1 (es)
ZA (1)	ZA200904014B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TW200530269A (en)	2003-12-12	2005-09-16	Chugai Pharmaceutical Co Ltd	Anti-Mpl antibodies
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9493569B2 (en)	2005-03-31	2016-11-15	Chugai Seiyaku Kabushiki Kaisha	Structural isomers of sc(Fv)2
JP5085322B2 (ja)	2005-06-10	2012-11-28	中外製薬株式会社	ｓｃ（Ｆｖ）２を含有する医薬組成物
EP1976877B2 (en)	2005-11-30	2016-10-05	AbbVie Inc.	Monoclonal antibodies against amyloid beta protein and uses thereof
CA2628703C (en)	2005-11-30	2019-10-29	Abbott Laboratories	Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
JP5145241B2 (ja) *	2005-12-12	2013-02-13	エフ．ホフマン−ラロシュアーゲー	可変領域におけるグリコシル化を有するアミロイドβに対する抗体
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
SG10201505369QA (en)	2007-10-05	2015-08-28	Genentech Inc	Use of anti-amyloid beta antibody in ocular diseases
ES2759075T3 (es)	2008-03-14	2020-05-07	Biocon Ltd	Un anticuerpo monoclonal y un método del mismo
JP6146949B2 (ja) *	2008-06-20	2017-06-21	ノバルティスアーゲー	凝集が低減された免疫グロブリン
MX2011002402A (es) *	2008-09-19	2011-04-05	Hoffmann La Roche	Formulacion de anticuerpo novedosa.
EP2346900A1 (en)	2008-10-29	2011-07-27	Wyeth LLC	Methods for purification of single domain antigen binding molecules
MX345226B (es) *	2008-10-29	2017-01-20	Ablynx Nv	Formulaciones de moleculas de union a antigeno de dominio sencillo.
MX2011005051A (es) *	2008-11-17	2011-06-01	Genentech Inc	Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
WO2010069858A1 (en) *	2008-12-19	2010-06-24	F. Hoffmann-La Roche Ag	Pharmaceutical composition
WO2010100179A2 (en) *	2009-03-05	2010-09-10	Novartis Ag	Self-forming gel system for sustained drug delivery
EP2501408B1 (en) *	2009-11-20	2020-05-27	Biocon Limited	Formulations of antibody
WO2011080209A2 (en) *	2009-12-29	2011-07-07	F. Hoffmann-La Roche Ag	Novel antibody formulation
AR080428A1 (es)	2010-01-20	2012-04-11	Chugai Pharmaceutical Co Ltd	Formulaciones liquidas estabilizadas contentivas de anticuerpos
US9795674B2 (en)	2010-02-26	2017-10-24	Novo Nordisk A/S	Stable antibody containing compositions
SI2542257T1 (en)	2010-03-01	2018-01-31	Bayer Healthcare Llc	Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
MX2012009460A (es)	2010-03-03	2012-09-12	Boehringer Ingelheim Int	Polipeptidos biparatopicos de union abeta.
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
CA2800188A1 (en)	2010-05-28	2011-12-01	Novo Nordisk A/S	Stable multi-dose compositions comprising an antibody and a preservative
KR101713365B1 (ko)	2010-07-30	2017-03-08	에이씨 이뮨 에스.에이.	안전하고 기능적인 인간화 항 베타-아밀로이드 항체
MX358739B (es)	2010-08-14	2018-09-03	Abbvie Inc Star	Proteinas de union a amiloide beta.
WO2012028683A1 (en) *	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery
WO2012151199A1 (en)	2011-05-02	2012-11-08	Immunomedics, Inc.	Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2012250872B2 (en) *	2011-05-02	2017-07-13	Millennium Pharmaceuticals, Inc.	Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
HK1198689A1 (en) *	2011-10-25	2015-05-29	Prothena Biosciences Limited	Antibody formulations and methods
WO2013131866A1 (en) *	2012-03-08	2013-09-12	F. Hoffmann-La Roche Ag	Abeta antibody formulation
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
EP2830658B1 (en) *	2012-03-26	2018-10-10	Sanofi	Stable igg4 binding agent formulations
US20130281355A1 (en)	2012-04-24	2013-10-24	Genentech, Inc.	Cell culture compositions and methods for polypeptide production
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US8883979B2 (en) *	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US8613919B1 (en)	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
EP2968538A1 (en) *	2013-03-15	2016-01-20	Bayer HealthCare LLC	Anti-prolactin receptor antibody formulations
EP3024485B1 (en)	2013-07-23	2020-11-18	Biocon Limited	Use of a cd6 binding partner and method based thereon
US20160114000A1 (en)	2014-10-24	2016-04-28	Merck Sharp & Dohme Corp.	Co-agonists of the glucagon and glp-1 receptors
EP3207936B1 (en) *	2014-11-18	2021-04-21	Shionogi & Co., Ltd.	Stable peptide composition
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN104946616A (zh) *	2015-05-12	2015-09-30	骏实生物科技(上海)有限公司	一种用于体外诊断试剂的通用固体稳定剂及其使用方法
AR104847A1 (es) *	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
IL302486A (en)	2015-06-24	2023-06-01	Hoffmann La Roche	Antibodies against the transnephrine receptor with adapted affinity
RS64263B1 (sr) *	2015-08-19	2023-07-31	Astrazeneca Ab	Stabilna anti-ifnar1 formulacija
EP3352790A1 (en) *	2015-09-22	2018-08-01	Pfizer Inc	Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
KR20250007038A (ko)	2015-10-02	2025-01-13	에프. 호프만-라 로슈 아게	이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN106620691B (zh) *	2015-11-04	2020-08-21	信达生物制药(苏州)有限公司	一种重组全人源抗ctla-4单克隆抗体制剂及其应用
SG11201804961UA (en)	2015-12-30	2018-07-30	Genentech Inc	Formulations with reduced degradation of polysorbate
CN106199007B (zh) *	2016-08-03	2017-04-05	烟台普罗吉生物科技发展有限公司	蛋白保护剂
JP7071974B2 (ja)	2016-10-21	2022-05-19	バイオコン・リミテッド	モノクローナル抗体および狼瘡の処置のための使用の方法
CN106913869B (zh) *	2017-03-17	2020-07-28	信达生物制药(苏州)有限公司	一种抗ctla-4单克隆抗体制剂及其应用
CN110352201A (zh)	2017-04-03	2019-10-18	免疫医疗公司	用于癌症疗法的抗体药物缀合物的皮下施用
EP3672631B9 (en) *	2017-08-22	2023-06-28	Biogen MA Inc.	Pharmaceutical compositions containing anti-beta amyloid antibodies
CN108373494A (zh) *	2018-02-27	2018-08-07	武汉伊艾博科技有限公司	一种防止重组蛋白质降解的保护技术
CR20210435A (es)	2019-02-18	2021-09-20	Lilly Co Eli	Formulación de anticuerpos terapéuticos
CN112618482A (zh) *	2019-09-24	2021-04-09	江苏恒瑞医药股份有限公司	新型蛋白制剂
CN112741804A (zh) *	2019-10-31	2021-05-04	上海君实生物医药科技股份有限公司	含有抗pd-l1抗体的稳定制剂
CN113116812A (zh) *	2019-12-30	2021-07-16	百奥泰生物制药股份有限公司	含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
WO2022072255A1 (en) *	2020-09-30	2022-04-07	Merck Sharp & Dohme Corp.	Binding proteins and antigen binding fragments thereof that bind abeta
US20240417451A1 (en)	2023-05-31	2024-12-19	Hoffmann-La Roche Inc.	Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies
CN117088974B (zh) *	2023-08-14	2024-02-13	武汉健昊生物科技有限公司	一种抗体保存液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6685940B2 (en) *	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
DE60235013D1 (de) *	2001-07-25	2010-02-25	Facet Biotech Corp	Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
AR038568A1 (es) *	2002-02-20	2005-01-19	Hoffmann La Roche	Anticuerpos anti-a beta y su uso
EP3178492A1 (en) *	2003-04-04	2017-06-14	Genentech, Inc.	High concentration antibody and protein formulations
GT200600031A (es) *	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
DOP2006000022A (es) *	2005-01-28	2006-08-15	Wyeth Corp	Formulaciones líquidas estabilizadas de polipetidos
JP5145241B2 (ja) *	2005-12-12	2013-02-13	エフ．ホフマン−ラロシュアーゲー	可変領域におけるグリコシル化を有するアミロイドβに対する抗体
EP1998806A1 (en) *	2006-03-28	2008-12-10	F. Hoffmann-Roche AG	Anti-igf-1r human monoclonal antibody formulation

2007
- 2007-12-11 AR ARP070105523A patent/AR064220A1/es unknown
- 2007-12-11 EP EP07856573A patent/EP2094729A1/en not_active Withdrawn
- 2007-12-11 BR BRPI0721097-3A patent/BRPI0721097A2/pt not_active IP Right Cessation
- 2007-12-11 AU AU2007331712A patent/AU2007331712A1/en not_active Abandoned
- 2007-12-11 JP JP2009540650A patent/JP2010512356A/ja not_active Withdrawn
- 2007-12-11 CN CNA2007800455861A patent/CN101553504A/zh active Pending
- 2007-12-11 KR KR1020097013954A patent/KR20090104017A/ko not_active Withdrawn
- 2007-12-11 PE PE2007001764A patent/PE20081477A1/es not_active Application Discontinuation
- 2007-12-11 RU RU2009126420/10A patent/RU2009126420A/ru not_active Application Discontinuation
- 2007-12-11 CL CL200703583A patent/CL2007003583A1/es unknown
- 2007-12-11 TW TW096147285A patent/TW200831133A/zh unknown
- 2007-12-11 WO PCT/EP2007/010825 patent/WO2008071394A1/en not_active Ceased
- 2007-12-11 US US12/448,190 patent/US20110070225A1/en not_active Abandoned
- 2007-12-11 MX MX2009006199A patent/MX2009006199A/es not_active Application Discontinuation
- 2007-12-11 CA CA002671968A patent/CA2671968A1/en not_active Abandoned
2009
- 2009-05-21 CR CR10823A patent/CR10823A/es not_active Application Discontinuation
- 2009-05-26 IL IL198963A patent/IL198963A0/en unknown
- 2009-06-08 MA MA31963A patent/MA30975B1/fr unknown
- 2009-06-09 ZA ZA200904014A patent/ZA200904014B/xx unknown
- 2009-06-11 EC EC2009009403A patent/ECSP099403A/es unknown
- 2009-07-07 NO NO20092586A patent/NO20092586L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL198963A0 (en)	2011-08-01
MX2009006199A (es)	2009-06-22
WO2008071394A1 (en)	2008-06-19
NO20092586L (no)	2009-07-17
PE20081477A1 (es)	2008-10-18
RU2009126420A (ru)	2011-01-20
US20110070225A1 (en)	2011-03-24
EP2094729A1 (en)	2009-09-02
TW200831133A (en)	2008-08-01
ECSP099403A (es)	2009-07-31
MA30975B1 (fr)	2009-12-01
CR10823A (es)	2009-08-12
AR064220A1 (es)	2009-03-18
AU2007331712A1 (en)	2008-06-19
CA2671968A1 (en)	2008-06-19
CN101553504A (zh)	2009-10-07
BRPI0721097A2 (pt)	2014-07-01
ZA200904014B (en)	2010-04-28
KR20090104017A (ko)	2009-10-05
AU2007331712A2 (en)	2009-07-30
JP2010512356A (ja)	2010-04-22

Similar Documents

Publication	Publication Date	Title
CL2007003583A1 (es)	2008-07-18	Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
CL2004001011A1 (es)	2005-03-18	Compuestos azabiciclicos derivados de n-arilsulfonilpiperidinas; inhibidores de la deposicion de la proteina beta amiloide; composicion farmaceutica; y su uso para el tratamiento del alzheimer y enfermedades neurodegenerativas.
CL2008001868A1 (es)	2008-10-17	Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2007001918A1 (es)	2008-03-28	Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2007003192A1 (es)	2008-06-20	Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario.
CL2007003262A1 (es)	2008-05-30	Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
BRPI0615150A2 (pt)	2017-06-20	agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
DOP2006000099A (es)	2006-10-31	Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos
BRPI0816255A2 (pt)	2015-03-17	Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CL2007002018A1 (es)	2008-05-09	Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2007002920A1 (es)	2008-06-06	Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2008001960A1 (es)	2009-11-27	Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
BRPI0811267A2 (pt)	2014-10-07	Variante de fenilanina amônia-liase procariótica, composição farmacêutica, método para o tratamento de uma doença, uso de uma variante de fenilalanina amônia-liase procariótica, método para o tratamento de uma condição, e, variante de fenilalanina amônia-liase de anabaena variabilis.
CL2008000127A1 (es)	2008-05-23	Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
CL2008000691A1 (es)	2008-09-12	Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI1012993A2 (pt)	2018-01-16	"uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
CL2007003756A1 (es)	2008-08-22	Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2007000806A1 (es)	2008-05-30	Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
WO2007022380A3 (en)	2007-06-21	Bis-aryl amide compounds and methods of use
CL2011001098A1 (es)	2012-02-24	Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
CL2007002897A1 (es)	2008-03-07	Uso de un antagonista (sartan) del receptor 1 (at-1) de angiotensina ii para la preparacion de una composicion farmaceutica para el tratamiento de una enfermedad generalizada en gatos; metodo para la profilaxis o el tratamiento de una enfermedad en g
BRPI0922435A2 (pt)	2018-09-11	"composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
CL2008000910A1 (es)	2008-11-21	Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.